文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

贝达喹啉耐药结核的治疗结局:回顾性匹配队列研究

Treatment outcomes of bedaquiline-resistant tuberculosis: a retrospective and matched cohort study.
PubMed 文献 · Lancet Infect Dis · 2025-06-18

在南非东伦敦结核病转诊医院开展的回顾性队列研究,纳入82例贝达喹啉耐药结核患者并与贝达喹啉敏感RR结核1:1匹配。WHO不良结局占67%(54/81),18个月无结核生存52%(43/82),死亡23%(19/82)。

要点

  • 贝达喹啉耐药结核WHO不良结局54/81(67%),其中治疗失败35/81(43%)。
  • 18个月时无结核生存43/82(52%),死亡19/82(23%),存活者中50/63(79%)仍在治疗。

核心结论

  • 当前贝达喹啉耐药结核治疗方案导致疗程延长、微生物学应答延迟和临床结局不佳。
  • 实施更快的耐药检测(包括靶向下一代测序)以及在随机对照试验中获取新治疗选择,是结核病规划的优先事项。

研究设计与样本

  • 南非东伦敦结核病转诊医院的回顾性队列研究,贝达喹啉耐药结核病例与贝达喹啉敏感RR结核对照按基线培养状态、年龄和HIV状态1:1匹配。
  • 病例为2018年1月1日至2023年6月30日鉴定出表型贝达喹啉耐药结核分枝杆菌分离株的13岁及以上患者,共82例。
  • 对照来自同一机构重叠期间的前瞻性观察研究,为确诊贝达喹啉敏感结核者。
  • 主要结局包括痰培养转阴(SCC)时间、改良WHO定义的不良结局和至18个月的无结核生存(存活、SCC且仍在 care 或完成治疗)。
  • 调整分析使用Cox比例风险模型和logistic回归模型。

主要发现

  • 82例贝达喹啉耐药结核患者中57例(70%)HIV阳性。
  • 72/82例(88%)处方贝达喹啉,32/82例(39%)处方美罗培南(联合阿莫西林-克拉维酸)。
  • 与贝达喹啉同时最常处方的药物包括氯法齐明、利奈唑胺和特立齐酮。
  • 贝达喹啉耐药组治疗开始后SCC中位时间175天(IQR 100-254),匹配对照32天(IQR 30-42)。

关键数值与推荐

  • 贝达喹啉耐药结核患者WHO治疗结局不良54/81例(67%),其中治疗失败35/81例(43%)。
  • 18个月时,43/82例(52%)达到无结核生存,19/82例(23%)死亡,63例存活者中50例(79%)仍在治疗。

临床怎么用

  • 原文未提供具体临床实践推荐。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rising prevalence of bedaquiline resistance undermines benefits from this life-saving drug for rifampicin-resistant tuberculosis (RR tuberculosis). Despite increasing awareness, patient-level outcomes for bedaquiline-resistant tuberculosis have not been well characterised and case management has been poorly defined. METHODS: We did a retrospective cohort study of bedaquiline-resistant tuberculosis with matched RR tuberculosis controls at a tuberculosis referral hospital in East London, South Africa. Cases included patients aged 13 years or older with a phenotypic bedaquiline-resistant Mycobacterium tuberculosis isolate identified between Jan 1, 2018 and June 30, 2023. Controls with confirmed bedaquiline-susceptible tuberculosis, matched 1:1 by baseline culture status, age, and HIV status, were selected from a prospective observational study conducted during an overlapping period at the same facility. Primary outcomes included time to sputum culture conversion (SCC), a modified WHO-defined unfavourable outcome, and tuberculosis-free survival (alive, with SCC, and in care or treatment completed) up until 18 months. Adjusted analyses used Cox proportional hazards and logistic regression models. FINDINGS: 82 patients with bedaquiline-resistant tuberculosis were included, 57 (70%) of whom were HIV positive. Bedaquiline was prescribed for 72 (88%) of 82 patients and meropenem (plus amoxicillin-clavulanate) for 32 (39%) of 82. Together with bedaquiline, the most frequently prescribed drugs included clofazimine, linezolid, and terizidone. Median time to SCC after treatment initiation was 175 days (IQR 100-254) in the bedaquiline-resistant cohort and 32 days (30-42) in matched controls. In the analysis of the combined cohorts, bedaquiline resistance (adjusted hazard ratio 0·03, 95% CI 0·0023-0·29, p=0·003) was associated with longer time to SCC when adjusted for baseline microscopy grade and baseline fluoroquinolone resistance. WHO treatment outcomes in those with bedaquiline-resistant tuberculosis were unfavourable in 54 (67%) of 81 patients, driven by treatment failure in 35 (43%) of 81. At 18 months, 43 (52%) of 82 patients had reached tuberculosis-free survival, 19 (23%) of 82 had died, and 50 (79%) of 63 survivors were still on treatment. INTERPRETATION: Current treatment options for bedaquiline-resistant tuberculosis result in prolonged therapy, delayed microbiological responses, and poor clinical outcomes. Implementation of more rapid resistance testing, including targeted next-generation sequencing, and access to novel treatment options within randomised controlled trials for bedaquiline-resistant tuberculosis, are priorities for tuberculosis programmes. FUNDING: The South African Medical Research Council.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Mdlenyani L, Mohamed Z, Stadler JAM, et al. Treatment outcomes of bedaquiline-resistant tuberculosis: a retrospective and matched cohort study. Lancet Infect Dis. 2025. PMID: 40543523. doi:10.1016/S1473-3099(25)00218-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。